From: Ibrutinib in B-cell lymphoma: single fighter might be enough?
Disease | Study (year) | Phase | Study details | Efficacy | Refs. | |
---|---|---|---|---|---|---|
TN CLL | Byrd et al. (2018) | Ib/II | 7-year follow up, 31 pts | ORR 87%, PFS 80%, OS 75% | [13] | |
 | O’Brien et al. (2014) | Ib/II | 31 elderly pts | Objective response 71%, CR 13%, PR 55% | [15] | |
 | Burger et al. (2015) | III | 269 elderly pts to compare ibrutinib with chloramnucil | ORR (86% vs. 35%), 18.4-month PFS (not reached vs. 18.9 months); 24-month OS (98% vs. 85%) | [39] | |
R/R CLL | Byrd et al. (2018) | Ib/II | 7-year follow up, 101 pts | ORR 89%, PFS 32%, OS 52% | [13] | |
 | Jones et al. (2018) | III | 230 pts with del17p | 30-month PFS 57%, OS 69% | [1] | |
 | Byrd et al. (2013) | Ib/II | 85 pts, the majority of whom were considered to have high-risk disease, 51 received 420 mg, 34 received 840 mg | ORR (71% vs. 71%), PR with lymphocytosis (20% vs. 15%), 24-month OS and PFS were 83% and 75% | [11] | |
 | O’Brien et al. (2016) | II | 145 pts with del17p | ORR 83%, 26-month PFS 63%, 26-month OS 75%, | [12] | |
 | Byrd et al. (2014) | III | 391 pts at risk for a poor outcome, to compare ibrutinib with ofatumumab | ORR (42.6% vs. 4.1%), PFS 88% and PR with lymphocytosis of ibrutinib group was 20%, 12-month OS (90% vs. 81%) | [14] | |
R/R MCL | Jeon et al. (2019) | NA | 33 pts | ORR 33%, OS 35.1 months, PFS 27.4 months | [21] | |
 | Wang et al. (2015) | II | Long-term follow up of 111 pts, at a dose of 560 mg once daily | ORR 67%, CR 23%, 24-month OS 47%, 24-month PFS 31% | [17] | |
 | Dreyling et al. (2016) | III | 280 pts to compare ibrutinib (n = 139) with temsirolimus (n = 141) | ORR (72% vs. 40%), CR with ibrutinib was 19%, median PFS (14.6 vs. 6.2 months), OS (not reached vs. 21.3 months) | [19] | |
R/R FL | Advani et al. (2013) | I | 56 pts | ORR 38% | [29] | |
 | Bartlett et al. (2017) | II | 40 pts with ibrutinib 560 mg once daily | ORR 37.5%, CR 12.5%, 2-year PFS 20.4%, median PFS 14 months | [30] | |
R/R ABC-DLBCL | Wilson et al. (2017) | I/II | 38 pts | CR or PR 37% | [32] | |
PCNSL | Grommes et al. (2017) | I | 13 pts | ORR 77% | [34] | |
 | Lionakis et al. (2017) | Ib | 18 pts | PR 83% | [35] | |
R/R WM | Dimopoulos et al. (2016) | III | 31 rituximab- refractory pts with a dose of 420Â mg | ORR 90%, MRR 71%, OS 97%, PFS 86% | [44] | |
 | Treon et al. (2015) | II | 63 pts with ibrutinib 420 mg once daily | ORR 90.5%, MRR 73%, PFS 69.1%, OS 95.2% | [25] | |
R/R MZL | Noy et al. (2016) | II | 63 pts with ibrutinib 560Â mg once daily | ORR 48% (6 CRs, 26 PRs) | [28] |